Cohort · P3-PDA-C1432Active studySynthetic mock data
Arm A — escalation responders
Owner AW · last updated 2026-04-21
Size
142
Status
locked
Inclusion criteria
4
Exclusion criteria
3
Definition
Inclusion
- +Confirmed PDA on histology
- +ECOG 0-1
- +Measurable disease per RECIST 1.1
- +Randomized to dose-escalation arm
Exclusion
- −Prior systemic therapy < 12 months
- −Active CNS metastases
- −Concurrent investigational agent
lockedP3-PDA-C1432Owner AWLast updated 2026-04-21
Enrollment over time
From wk 0 (n=0) to wk 28 (n=142)
Subjects in cohort (12)
| Subject | MRN | Age / Sex | Site | Enrolled | Status |
|---|---|---|---|---|---|
| PDA-A-001 Maria Alvarez | MRN 6024100 | 48 / F | Site 03 — Chicago | 2025-08-01 | withdrawn |
| PDA-A-002 Henry Müller | MRN 6024101 | 51 / M | Site 09 — Munich | 2025-08-06 | active |
| PDA-A-003 Rachel Sørensen | MRN 6024102 | 54 / F | Site 12 — Singapore | 2025-08-11 | active |
| PDA-A-004 Robert Adebayo | MRN 6024103 | 57 / M | Site 14 — Boston | 2025-08-16 | active |
| PDA-A-005 Priya Iversen | MRN 6024104 | 60 / F | Site 18 — Toronto | 2025-08-21 | active |
| PDA-A-006 Theo O'Connor | MRN 6024105 | 63 / M | Site 22 — Madrid | 2025-08-26 | active |
| PDA-A-007 Sara Tanaka | MRN 6024106 | 66 / F | Site 03 — Chicago | 2025-08-31 | active |
| PDA-A-008 Antonio Marquez | MRN 6024107 | 69 / M | Site 09 — Munich | 2025-09-05 | active |
| PDA-A-009 Aisha Hassan | MRN 6024108 | 72 / F | Site 12 — Singapore | 2025-09-10 | active |
| PDA-A-010 Omar Singh | MRN 6024109 | 75 / M | Site 14 — Boston | 2025-09-15 | active |
| PDA-A-011 Fatima Patel | MRN 6024110 | 48 / F | Site 18 — Toronto | 2025-09-20 | active |
| PDA-A-012 David Garcia | MRN 6024111 | 51 / M | Site 22 — Madrid | 2025-09-25 | completed |
Linked study
P3-PDA-C1432
RECIST-style longitudinal research workspace
Progression-free survival at 32 weeks · 314/380 enrolled
Sister cohorts in P3-PDA-C1432
Endpoints attached to this protocol
Cross-links